A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

A Phase 1, Single-center, Randomized, Vehicle-controlled, Parallel-cohort Study Of Crisaborole Ointment 2% To Evaluate The Skin Irritation Potential In Adult Japanese Healthy Subjects, And To Evaluate The Safety, Tolerability And Pharmacokinetics In Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03260595

Enrollment

Registered

2017-08-24

Start date

2017-09-13

Completion date

2017-11-27

Last updated

2019-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis, Healthy

Brief summary

This is a Phase 1 parallel-cohort study of crisaborole ointment 2% to evaluate the skin irritation potential in adult Japanese healthy subjects in Cohort 1, and to evaluate the safety, tolerability and PK in adult Japanese subjects with mild to moderate AD in Cohort 2.

Interventions

DRUGCrisaborole ointment 2%

Crisaborole ointment 2%

DRUGVehicle

Vehicle

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

Cohort 1 1. Healthy male Japanese subjects who, at the time of screening, are between the ages of 20 and 55 years, inclusive. 2. Healthy skin on which reddening can be easily recognized in the area of the test fields. Cohort 2 1. Male or female Japanese subjects aged 20 years to 55 years (inclusive) at the time of screening, and in generally good health except for AD. 2. Diagnosis of AD based on the criteria of Hanifin and Rajka (1980). 3. Has at least 25% Treatable %BSA on Day 1 (excluding the scalp and designated venous access areas). 4. Has an Investigator's static global assessment (ISGA) score of Mild (2) or Moderate (3) on Day 1.

Exclusion criteria

Cohort 1 1. Subjects who have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction. 2. Subjects who have psoriasis and/or active AD/eczema. 3. Subjects who have a history of AD. 4. Subjects who have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site. 5. Known sensitivity to any of the components of the investigational products. 6. History of the rash to the adhesive plaster, contact dermatitis to metal, or cosmetic and household articles. Cohort 2 1. Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent dermatological conditions other than AD), significant physical examination or laboratory findings that may interfere with study objectives, in the Investigator's opinion. 2. Has unstable AD or a consistent requirement for strong to strongest potency topical corticosteroids to manage AD signs and symptoms. 3. Has a significant active systemic or localized infection, including known actively infected AD. 4. Has a history or evidence of clinically significant or severe allergies (eg, seasonal, pet dander, environmental, food) requiring acute or chronic treatment. 5. Has recent or anticipated concomitant use of topical or systemic therapies that might alter the course of AD. 6. Has a history of recent (within 4 weeks of Day 1) sunbathing, tanning bed use, or ultraviolet (UV) light B therapy (UVB) or psoralen plus UVA \[PUVA\]). 7. Has a known sensitivity to any of the components of crisaborole ointment 2%. 8. Pregnant female subjects; breastfeeding female subjects; female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.

Design outcomes

Primary

Measure	Time frame	Description
Cohort 1: Skin Irritation Index	Day 3 to 4	The skin irritation index is a common measure of skin irritation potential (safety criteria) of investigational product and derived using skin irritation scores. Individual skin irritation score ranges from 0-4, where 0 = no reaction, 0.5 = mild erythema, 1 = erythema, 2 = erythema with edema and papula, 3 = erythema with edema, papula and small water blister, 4 = large water blister, higher score indicates more skin irritation. For each investigational product, the skin irritation index was calculated as the sum of the maximum individual skin irritation scores divided by the number of evaluable participants and multiplied by 100, which ranged from 0 to 400; where, lower score indicated less skin irritation and higher score indicated more skin irritation.
Cohort 2: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	Baseline up to Day 36	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose of study drug (up to Day 36) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.
Cohort 2: Number of Participants With Clinically Significant Vital Signs Abnormalities	Baseline up to end of treatment (Day 8)	Vital signs included pulse rate and blood pressure. Clinical significance of vital signs was determined at the investigator's discretion.
Cohort 2: Number of Participants With Laboratory Tests Abnormalities	Baseline up to end of treatment (Day 8)	Laboratory tests abnormalities included: hematology (haemoglobin\[Hb\], haematocrit and erythrocytes\<0.8\lower limit of normal\[LLN\]; erythrocyte mean corpuscular volume, erythrocyte mean corpuscular Hb and erythrocyte mean corpuscular Hb concentration \<0.9\LLN and \>1.1\upper limit of normal\[ULN\]; platelets \<0.5\LLN and \>1.75\ULN; leukocytes \<0.6\LLN and \>1.5\ULN; lymphocytes/leukocytes\[%\], neutrophils/leukocytes\[%\] \<0.8\LLN and \>1.2\ULN; basophils/leukocytes\[%\], eosinophils/leukocytes\[%\], monocytes/leukocytes\[% \]\>1.2\ULN); clinical chemistry(bilirubin\>1.5\ULN; aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase\>3.0\ULN; protein and albumin\<0.8\LLN and \>1.2\ULN; urea nitrogen and creatinine \>1.3\ULN; urate\>1.2\ULN; sodium \<0.95\LLN and \>1.05\ULN; potassium, chloride and calcium \<0.9\LLN and \>1.1\ULN; fasting glucose \<0.6\LLN and \>1.5\ULN); and urinalysis (pH \<4.5 and \>8; glucose, ketones, protein, Hb, urobilinogen, bilirubin, nitrite and leukocyte esterase \>=1).
Cohort 2: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities	Baseline up to end of treatment (Day 8)	Criteria for clinically significant ECG abnormalities included: QT interval \>=500 milliseconds (msec); QT interval corrected using the Fridericia's formula (QTcF) \>=450 msec to \<480 msec, \>=480 msec and \>=500 msec; increase from baseline in QTcF interval \>=30 msec to \<60 msec and \>=60 msec.

Secondary

Measure	Time frame	Description
Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Tau (12 Hours Dosing Interval) (AUCtau) of Crisaborole and Its Identified Main Oxidative Metabolites	Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8	AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole. AUC tau was defined as area under the plasma concentration-time curve from time 0 to time tau, the dosing interval, where tau =12 hours.
Cohort 1: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	Baseline up to Day 29	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose of study drug (up to Day 29) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.
Cohort 2: Accumulation Ratio for AUCtau (Rac [AUCtau]) of Crisaborole and Its Identified Main Oxidative Metabolites	Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and 8	AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole. Accumulation ratio for AUCtau (Rac) was calculated as area under the curve from time zero to end of dosing interval (AUCtau) on Day 8 divided by AUCtau on Day 1. Dosing interval = 12 hours.
Cohort 2: Accumulation Ratio for Cmax (Rac [Cmax]) of Crisaborole and Its Identified Main Oxidative Metabolites	Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and 8	AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole. Accumulation ratio for Cmax (Rac, Cmax) was calculated as Cmax on Day 8 divided by Cmax on Day 1. Cmax was the maximum plasma concentration of Crisaborole and its identified main oxidative metabolites.
Cohort 2: Maximum Observed Plasma Concentration (Cmax) of Crisaborole and Its Identified Main Oxidative Metabolites	Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8	AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole.
Cohort 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crisaborole and Its Metabolites	Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8	AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole.
Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Measurable Concentration (AUClast) of Crisaborole and Its Identified Main Oxidative Metabolites	Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8	AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole.
Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero to the 24 Hours Post-Dose (AUC24) of Crisaborole and Its Identified Main Oxidative Metabolites (AN7602 and AN8323)	Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and Day 8	AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole.

Countries

Japan

Participant flow

Participants by arm

Arm	Count
Cohort 1: Crisaborole Ointment 2% and Vehicle Crisaborole ointment 2% and matching vehicle was applied topically to 2 randomly assigned, adjacent sites on the skin area field at infrascapular area of the back respectively within each healthy participant under occlusive patch condition on Day 1. Ointment and vehicle were remained under occlusion for 48 hours. Target sites were identified at Baseline (Day 1) by investigator.	20
Cohort 2: Crisaborole Ointment 2% Crisaborole ointment 2% was applied topically to the treatable percent body surface area (%BSA: defined as percent of a participant's total BSA that is AD-involved and is not on the scalp or in designated venous access areas) of participants with AD twice daily from Days 2 to 7 and once only on Days 1 and 8. Treatable %BSA was calculated at Baseline (Day 1) by investigator.	10
Cohort 2: Vehicle Vehicle matched to Crisaborole ointment 2% was applied topically to the treatable %BSA (defined as percent of a participant's total BSA that AD-involved and is not on the scalp or in designated venous access areas) of participants with AD twice daily from Days 2 to 7 and once only on Days 1 and 8. Treatable %BSA was calculated at Baseline (Day 1) by investigator.	2
Total	32

Baseline characteristics

Characteristic	Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Crisaborole Ointment 2%	Cohort 2: Vehicle	Total
Age, Continuous	26.2 years STANDARD_DEVIATION 5.66	35.0 years STANDARD_DEVIATION 11.28	23.5 years STANDARD_DEVIATION 4.95	28.8 years STANDARD_DEVIATION 8.72
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	20 Participants	10 Participants	2 Participants	32 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	20 Participants	10 Participants	2 Participants	32 Participants
Race (NIH/OMB) Black or African American	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) White	0 Participants	0 Participants	0 Participants	0 Participants
Sex: Female, Male Female	0 Participants	0 Participants	0 Participants	0 Participants
Sex: Female, Male Male	20 Participants	10 Participants	2 Participants	32 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 20	0 / 10	0 / 2
other Total, other adverse events	0 / 20	9 / 10	2 / 2
serious Total, serious adverse events	0 / 20	0 / 10	0 / 2

Outcome results

Primary

Cohort 1: Skin Irritation Index

The skin irritation index is a common measure of skin irritation potential (safety criteria) of investigational product and derived using skin irritation scores. Individual skin irritation score ranges from 0-4, where 0 = no reaction, 0.5 = mild erythema, 1 = erythema, 2 = erythema with edema and papula, 3 = erythema with edema, papula and small water blister, 4 = large water blister, higher score indicates more skin irritation. For each investigational product, the skin irritation index was calculated as the sum of the maximum individual skin irritation scores divided by the number of evaluable participants and multiplied by 100, which ranged from 0 to 400; where, lower score indicated less skin irritation and higher score indicated more skin irritation.

Time frame: Day 3 to 4

Population: Safety analysis population included all participants who received at least one dose of study medication. Data for this outcome measure was not planned to be collected and analyzed for Cohort 2, as pre-specified in protocol.

Arm	Measure	Group	Value (NUMBER)
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 1: Skin Irritation Index	Vehicle	5.0 scores on a scale
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 1: Skin Irritation Index	Crisaborole ointment 2%	40.0 scores on a scale

Primary

Cohort 2: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

Criteria for clinically significant ECG abnormalities included: QT interval \>=500 milliseconds (msec); QT interval corrected using the Fridericia's formula (QTcF) \>=450 msec to \<480 msec, \>=480 msec and \>=500 msec; increase from baseline in QTcF interval \>=30 msec to \<60 msec and \>=60 msec.

Time frame: Baseline up to end of treatment (Day 8)

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities	0 Participants
Cohort 2: Vehicle	Cohort 2: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities	0 Participants

Primary

Cohort 2: Number of Participants With Clinically Significant Vital Signs Abnormalities

Vital signs included pulse rate and blood pressure. Clinical significance of vital signs was determined at the investigator's discretion.

Time frame: Baseline up to end of treatment (Day 8)

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Number of Participants With Clinically Significant Vital Signs Abnormalities	0 Participants
Cohort 2: Vehicle	Cohort 2: Number of Participants With Clinically Significant Vital Signs Abnormalities	0 Participants

Primary

Cohort 2: Number of Participants With Laboratory Tests Abnormalities

Laboratory tests abnormalities included: hematology (haemoglobin\[Hb\], haematocrit and erythrocytes\<0.8\*lower limit of normal\[LLN\]; erythrocyte mean corpuscular volume, erythrocyte mean corpuscular Hb and erythrocyte mean corpuscular Hb concentration \<0.9\*LLN and \>1.1\*upper limit of normal\[ULN\]; platelets \<0.5\*LLN and \>1.75\*ULN; leukocytes \<0.6\*LLN and \>1.5\*ULN; lymphocytes/leukocytes\[%\], neutrophils/leukocytes\[%\] \<0.8\*LLN and \>1.2\*ULN; basophils/leukocytes\[%\], eosinophils/leukocytes\[%\], monocytes/leukocytes\[% \]\>1.2\*ULN); clinical chemistry(bilirubin\>1.5\*ULN; aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase\>3.0\*ULN; protein and albumin\<0.8\*LLN and \>1.2\*ULN; urea nitrogen and creatinine \>1.3\*ULN; urate\>1.2\*ULN; sodium \<0.95\*LLN and \>1.05\*ULN; potassium, chloride and calcium \<0.9\*LLN and \>1.1\*ULN; fasting glucose \<0.6\*LLN and \>1.5\*ULN); and urinalysis (pH \<4.5 and \>8; glucose, ketones, protein, Hb, urobilinogen, bilirubin, nitrite and leukocyte esterase \>=1).

Time frame: Baseline up to end of treatment (Day 8)

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Number of Participants With Laboratory Tests Abnormalities	7 Participants
Cohort 2: Vehicle	Cohort 2: Number of Participants With Laboratory Tests Abnormalities	1 Participants

Primary

Cohort 2: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose of study drug (up to Day 36) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.

Time frame: Baseline up to Day 36

Population: Safety analysis population included all participants who received at least one dose of study medication.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	AEs	9 Participants
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	SAEs	0 Participants
Cohort 2: Vehicle	Cohort 2: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	AEs	2 Participants
Cohort 2: Vehicle	Cohort 2: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	SAEs	0 Participants

Secondary

Cohort 1: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 28 days after last dose of study drug (up to Day 29) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-serious AEs.

Time frame: Baseline up to Day 29

Population: Safety analysis population included all participants who received at least one dose of study medication.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 1: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	SAEs	0 Participants
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 1: Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)	AEs	0 Participants

Secondary

Cohort 2: Accumulation Ratio for AUCtau (Rac [AUCtau]) of Crisaborole and Its Identified Main Oxidative Metabolites

AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole. Accumulation ratio for AUCtau (Rac) was calculated as area under the curve from time zero to end of dosing interval (AUCtau) on Day 8 divided by AUCtau on Day 1. Dosing interval = 12 hours.

Time frame: Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and 8

Population: PK parameter analysis population was defined as all participants randomized and treated who had at least 1 of the PK parameters of primary interest. Data for this outcome measure was not planned to be collected and analyzed for Cohort 1, as pre-specified in protocol.

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Accumulation Ratio for AUCtau (Rac [AUCtau]) of Crisaborole and Its Identified Main Oxidative Metabolites	Crisaborole	1.209 ratio	Geometric Coefficient of Variation 25
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Accumulation Ratio for AUCtau (Rac [AUCtau]) of Crisaborole and Its Identified Main Oxidative Metabolites	AN7602	0.8688 ratio	Geometric Coefficient of Variation 19
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Accumulation Ratio for AUCtau (Rac [AUCtau]) of Crisaborole and Its Identified Main Oxidative Metabolites	AN8323	3.080 ratio	Geometric Coefficient of Variation 48

Secondary

Cohort 2: Accumulation Ratio for Cmax (Rac [Cmax]) of Crisaborole and Its Identified Main Oxidative Metabolites

AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole. Accumulation ratio for Cmax (Rac, Cmax) was calculated as Cmax on Day 8 divided by Cmax on Day 1. Cmax was the maximum plasma concentration of Crisaborole and its identified main oxidative metabolites.

Time frame: Pre-dose, 3, 12 and 24 hours post-dose on Day 1 and 8

Arm	Measure	Group	Value (GEOMETRIC_MEAN)	Dispersion
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Accumulation Ratio for Cmax (Rac [Cmax]) of Crisaborole and Its Identified Main Oxidative Metabolites	Crisaborole	1.007 ratio	Geometric Coefficient of Variation 32
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Accumulation Ratio for Cmax (Rac [Cmax]) of Crisaborole and Its Identified Main Oxidative Metabolites	AN7602	0.7247 ratio	Geometric Coefficient of Variation 24
Cohort 1: Crisaborole Ointment 2% and Vehicle	Cohort 2: Accumulation Ratio for Cmax (Rac [Cmax]) of Crisaborole and Its Identified Main Oxidative Metabolites	AN8323	2.638 ratio	Geometric Coefficient of Variation 52

Secondary

Cohort 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Tau (12 Hours Dosing Interval) (AUCtau) of Crisaborole and Its Identified Main Oxidative Metabolites

AN7602 and AN8323 were the main identified oxidative metabolites of Crisaborole. AUC tau was defined as area under the plasma concentration-time curve from time 0 to time tau, the dosing interval, where tau =12 hours.